What are the recommendations for the management of Helicobacter pylori infection after the third European consensus conference (Maastricht 3)?;Quelles recommandations pour le management de l'infection à Helicobacter pylori après la troisième conférence de consensus Européenne (Maastricht 3)?

Gastroenterologie Clinique et Biologique

Volumn 30, Issue 12, 2006, Pages 1361-1364

  Delchier, Jean Charles ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; QUINOLONE; RIFABUTIN; RIFAMPICIN;

BACTERIAL INFECTION; CONFERENCE PAPER; DISEASE ASSOCIATION; ENDOSCOPY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MEDICAL RESEARCH; NONHUMAN; PREVALENCE; SEROLOGY; STOMACH CANCER; STOMACH LYMPHOMA; STOMACH ULCER; TREATMENT INDICATION;

EID: 33846115774     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(06)73555-2     Document Type: Conference Paper

References (44)

1. Consensus development conference on Helicobacter pylori. Revised conclusions and recommendations of the Working group (1999). Gastroenterol Clin Biol 1999;23:C95-104.
2. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
3. Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002;122:1270-85.
4. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003;CD002096.
5. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 2000;321:659-64.
6. Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002;324:1012-6.
7. Sharma P, Vakil N. Review article: Helicobacter pylori and reflux disease. Aliment Pharmacol Ther 2003;17:297-305.
8. Graham DY. Changing patterns of peptic ulcer, gastro-oesophageal reflux disease and Helicobacter pylori: a unifying hypothesis. Eur J Gastroenterol Hepatol 2003;15:571-2.
9. McColl KE, Dickson A, El Nujumi A, El Omar E, Kelman A. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:101-5.
10. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002;97:2992-7.
11. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53:12-20.
12. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6.
13. Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000;46:615-21.
14. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
15. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998;352:1016-21.
16. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
17. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9-13.
18. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-8.
19. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-8.
20. DuBois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am J Gastroenterol 2005;100:453-9.
21. Annibale B, Marignani M, Monarca B, Antonelli G, Marcheggiano A, Martino G, et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med 1999;131:668-72.
22. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998;352:878.
23. Ciacci C, Sabbatini F, Cavallaro R, Castiglione F, Di Bella S, Iovino P, et al. Helicobacter pylori impairs iron absorption in infected individuals. Dig Liver Dis 2004;36:455-60.
24. Franchini M, Veneri D. Helicobacter pylori infection and immune thrombocytopenic purpura: an update. Helicobacter 2004;9:342-6.
25. Gisbert JP, Pajares JM. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 2004;20:1001-17.
26. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004;9:347-68.
27. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996;91:1138-44.
28. Rogge JD, Wagner DR, Carrico RJ, Glowinski EA, Mahoney SJ, Boguslaski RC, et al. Evaluation of a new urease reagent strip for detection of Helicobacter pylori in gastric biopsy specimens. Am J Gastroenterol 1995;90:1965-8.
29. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
30. Megraud F. Update on Therapeutic Options for Helicobacter pylori-related Diseases. Curr Infect Dis Rep 2005;7:115-20.
31. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003;17Suppl B:36B-40B.
32. Lamouliatte H, Megraud F, Delchier JC, Bretagne JF, Courillon-Mallet A, De Korwin JD, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003;18:791-7.
33. Toracchio S, Cellini L, Di Campli E, Cappello G, Malatesta MG, Ferri A, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:1639-43.
34. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
35. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49: 347-53.
36. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
37. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003;125:1636-44.
38. El Omar EM, Chow WH, Rabkin CS. Gastric cancer and H. pylori: Host genetics open the way. Gastroenterology 2001;121:1002-4.
39. Aragones N, Pollan M, Gustavsson P. Stomach cancer and occupation in Sweden: 1971-89. Occup Environ Med 2002;59:329-37.
40. Nozaki K, Shimizu N, Ikehara Y, Inoue M, Tsukamoto T, Inada K, et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci 2003;94:235-9.
41. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639-42.
42. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
43. Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Figueroa LS, Halperin D, et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 2004;13:4-10.
44. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.